检索结果-南通市图书馆

Tocilizumab in severe COVID-19-A randomized,double-blind,placebo-controlled trial

Infectious Medicine 2022年第2期1卷 88-94页

作者： Muhammad Irfan malik Sardar Al Fareed Zafar Fabiha Qayyum muna malik Muhammad Sohaib Asghar Muhammad Junaid Tahir Ammarah Arshad Fatima Khalil Hafiza Shafia Naz Mudassar Aslam Jodat Saleem Abdul Aziz Mustafa Usman Azhar Muhammad Naqash Zohaib Yousaf Postgraduate Medical Institute LahorePakistan Lahore General Hospital LahorePakistan Ameer-ud-Din Medical College LahorePakistan Dow University of Health Sciences-Ojha Campus KarachiPakistan Sheikh Zayed Medical College Rahim Yar KhanPakistan Hamad Medical Corporation DohaQatar

Background:The therapeutic effectiveness of interleukin-6 receptor inhibitor in critically ill hospitalized patients with coronavirus disease 2019(COVID-19)is ***:To evaluate the efficacy and safety of the outcome as recovery or death of tocilizumab for severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2)infection,we conducted a randomized,double-blinded,placebo-controlled phase 2 trial in critically ill COVID-19 adult *** patients were randomly assigned in a 4:1 ratio to receive standard medical treatment plus the recommended dose of either tocilizumab or the placebo *** was *** primary outcome was the recovery or death after administration of tocilizumab or a placebo *** secondary outcomes were clinical recovery or worsening of the patients’symptoms and inflammatory markers and discharge from the ***:Of 190 patients included in this study,152 received tocilizumab,and 38 received a *** duration of hospital stay of the interventional group was 12.9±9.2,while the placebo group had a more extended hospital stay(15.6±8.8).The mortality ratio for the primary outcome,ie,mortality or recovery in the tocilizumab group was 17.8%;p=0.58 by log-rank test).The mortality ratio in the placebo group was 76.3%;p=0.32 by log-rank test).The inflammatory markers in the tocilizumab group significantly declined by day 16 compared to the placebo ***:The use of tocilizumab was associated with decreased mortality,earlier improvement of inflamma-tory markers,and reduced hospital stay in patients with severe COVID-19.

关键词： Inflammatory Infectious Immunosuppression COVID-19 Therapy Trial

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：